Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 21

Results For "Non"

1170 News Found

Fortis Healthcare appoints Leo Puri as Chairman of the Board
People | December 28, 2024

Fortis Healthcare appoints Leo Puri as Chairman of the Board

Puri is an accomplished leader and financial sector veteran with over four decades of experience


Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab
News | December 27, 2024

Mankind Pharma and Innovent Biologics join forces for cancer care with Sintilimab

Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India


Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger
News | December 24, 2024

Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger

The transaction is expected to result in approximately $175 million to support further development of IMG-007


CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK's MHRA
News | December 22, 2024

CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK's MHRA

Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins


Reliance Digital Health Ltd to acquire 45% in Health Alliance Group
Digitisation | December 22, 2024

Reliance Digital Health Ltd to acquire 45% in Health Alliance Group

The investment will empower RDHL to develop a virtual diagnostic and care platform, expanding access to healthcare for underserved communities


Merck closes license agreement for LM-299
News | December 21, 2024

Merck closes license agreement for LM-299

Merck will record a pre-tax charge relating to the upfront payment of $588 million


Cipla launches India's first inhalable insulin ‘Afrezza’
News | December 19, 2024

Cipla launches India's first inhalable insulin ‘Afrezza’

Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management


Merck to discontinue KeyVibe and Keyform clinical trials
Diagnostic Center | December 17, 2024

Merck to discontinue KeyVibe and Keyform clinical trials

Merck has also decided to end the favezelimab clinical development program